|
Each tablet contains:
Composition:
Nevirapine......................................................................
200 mg
Lamivudine ....................................................................150
mg
Stavudine.........................................................................
30 mg
Indications:
Progressive or advanced HIV infection, in combination
with atleast 2 other antiretroviral
drugs.
Description:
Nevirapine binds directly to reverse
transcriptase (RT) and blocks the
RNA-dependent and DNA-dependent DNA
polymerase activities by causing a
disruption of the enzyme's catalytic
site. The activity of nevirapine does
not compete with template or nucleoside
triphosphates.
Lamivudine is a cytosine analog. After lamivudine
is triphosphorylated, it inhibits HIV
reverse transcription via viral DNA
chain termination and inhibits RNA- and
DNA-dependent DNA polymerase activities
of reverse transcriptase.
The monophosphate form of lamivudine is
incorporated into the viral DNA by
hepatitis B virus polymerase, resulting
in DNA chain termination.
Stavudine is an
analog
of
thymidine. It is
phosphorylated by cellular
kinases
into active triphosphate. Stavudine
triphosphate inhibits the HIV
reverse
transcriptase by competing
with natural substrate, thymidine
triphosphate. It also causes termination
of
DNA
synthesis by incorporating
into it.
Simultaneous use of
AZT
is not recommended, as it can inhibit
the intracellular
phosphorylation of stavudine.
Other anti-HIV drugs do not possess this
property.
Dosage :
Adult: 200mg once daily for first 14
days and if no rash appears increase to
200mg twice daily.
Children: 2 months-8 years: 4mg/kg once
daily for first 14 days and then if no
rash 7mg/kg twice daily (maximum:400mg
daily) 8-16 years (below 50kg): 4mg
once daily for 1st 14 days and then if
no rash, 4mg twice daily (maximum: 400mg
daily) Over 50kg: Adult dose.
Presentations:
MRP Retailer
Stockist
30 tablets
615.50
492.40 443.16
60 tablets
629.50
503.60 453.24
|
